Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) — Net Asset Quality Index
Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has a Net Asset Quality Index of 93.8% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥10.21 Billion minus total liabilities of CN¥631.40 Million yields net assets of CN¥9.58 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Chengdu Kanghong Pharmaceuticals Group C balance sheet liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Chengdu Kanghong Pharmaceuticals Group Co Ltd Net Asset Quality Index Over Time (2009–2025)
This chart shows how Chengdu Kanghong Pharmaceuticals Group Co Ltd's Net Asset Quality Index has evolved across 17 annual periods from 2009 to 2025. As of March 2026, the index stands at 93.8%, representing net assets of CN¥9.58 Billion against total assets of CN¥10.21 Billion CNY. For live market cap and overall valuation, see market value of Chengdu Kanghong Pharmaceuticals Group C.
Annual Net Asset Quality Index for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2025)
The table below presents the year-by-year Net Asset Quality Index for Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2025, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Chengdu Kanghong Pharmaceuticals Group C strategic capital allocation to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 93.5% | CN¥9.27 Billion | CN¥9.92 Billion | CN¥645.22 Million | ▲ +0.9 pp |
| 2024 | 92.6% | CN¥8.65 Billion | CN¥9.34 Billion | CN¥695.07 Million | ▲ +1.0 pp |
| 2023 | 91.6% | CN¥7.81 Billion | CN¥8.53 Billion | CN¥717.76 Million | ▲ +2.1 pp |
| 2022 | 89.5% | CN¥6.91 Billion | CN¥7.72 Billion | CN¥813.85 Million | ▲ +1.7 pp |
| 2021 | 87.8% | CN¥6.10 Billion | CN¥6.96 Billion | CN¥851.08 Million | ▲ +5.6 pp |
| 2020 | 82.2% | CN¥5.76 Billion | CN¥7.00 Billion | CN¥1.25 Billion | ▲ +2.9 pp |
| 2019 | 79.3% | CN¥4.62 Billion | CN¥5.83 Billion | CN¥1.21 Billion | ▲ +0.7 pp |
| 2018 | 78.6% | CN¥4.08 Billion | CN¥5.19 Billion | CN¥1.11 Billion | ▲ +1.4 pp |
| 2017 | 77.3% | CN¥3.54 Billion | CN¥4.59 Billion | CN¥1.04 Billion | ▼ 0.0 pp |
| 2016 | 77.3% | CN¥2.90 Billion | CN¥3.76 Billion | CN¥853.27 Million | ▼ -9.7 pp |
| 2015 | 87.0% | CN¥2.52 Billion | CN¥2.90 Billion | CN¥376.19 Million | ▲ +4.0 pp |
| 2014 | 83.0% | CN¥1.61 Billion | CN¥1.94 Billion | CN¥329.11 Million | ▲ +1.1 pp |
| 2013 | 82.0% | CN¥1.39 Billion | CN¥1.69 Billion | CN¥305.69 Million | ▲ +7.3 pp |
| 2012 | 74.7% | CN¥1.11 Billion | CN¥1.48 Billion | CN¥375.39 Million | ▲ +2.4 pp |
| 2011 | 72.3% | CN¥936.39 Million | CN¥1.30 Billion | CN¥359.58 Million | ▲ +9.2 pp |
| 2010 | 63.0% | CN¥624.85 Million | CN¥991.06 Million | CN¥366.21 Million | ▼ -2.5 pp |
| 2009 | 65.5% | CN¥539.75 Million | CN¥823.48 Million | CN¥283.73 Million | — |